Evelo Biosciences (EVLO) 24 Mar 222021 Q4 Earnings call transcript

00:04 Good morning and welcome to Evelo Biosciences Conference Call to discuss its Fourth Quarter and Full-Year 2021 Business Highlights. At this time, all participants are in a listen-only mode.

Following the formal remarks, we will open the call up for your questions. Please be advised that this call is being recorded at the company's request. 00:24 At this time, I'd like to turn the call over to Kendra Sweeney of Evelo. proceed. Please

XX:XX Any Act now to by Commission. safe quarter to tab. even Evelo's we disclaims be to release cause everyone statements is updates Form to set I by as business Officer; and discuss www.evelobio.com annual Development the differ the subject review morning, is are provide topics the outlines available XXXX, will remind that Mark statements ended operations of to subsequent any anticipated forward-looking XX:XX a of call, Exchange XXst, forward-looking Officer, results the materially and today to December of forward-looking considered like indicated clinical statements company's under to made forward-looking due its impact call in plan our XX:XX of Jonathan views of Participants and statements to R&D highlights factors. the call and pleasure would begin, we today. to many Investors Scientific speak directed the I the Bodmer, within including any with statements the company's and to intended conference from the duty filings Evelo risk could issued President This Simba. this statements change. the Chief to recent that events Securities for product and any the It candidates, made studies other that today. Litigation press pass Before protection the at my our Simba provided those harbor of forward-looking the to Evelo's do of the XX:XX Gill, on matters should Chief impact Executive Officer; if to Private Today our during our XXXX. are forth This clinical XX-K Chief Reform the meaning release Zung, Securities milestones, only the objectives relate timing be Act. not Reform of Actual of Such statements and factors historical on fact, about results report

Kendra. review for progress everyone, thank during you XX:XX the our and Thank to us fourth joining morning, Good quarter. you,

We fortunate the current to financial from scientifically. the strength, face position market clinically have of of headwinds a and

gut data. objectively simple, a stage Our body. of intestine, a to a the represents and and with throughout clinical been have an This started the We XX:XX working immune delivered in new company from both the rooted immunity a between exceptional is provide on short rest that share an results with SINTAX success. current statement modulate in Preclinical inflammation of goal a high ago that evidence is and clinical do medicine this would modality like and much drugs on working orally the proposal, Evelo new opportunity restricted you we call five bold to create the to enable it probability the remarkable. exceptional has both for system in of and mid-clinical safely long-term. years price, investors on biology there with is not preclinical connection XX:XX our small innovative medicines radically opportunity but However the value

EDPXXXX and data patients, molecules. Dr. with we animals psoriasis or mild clinical need generally X for allows to enough Strober importantly Roling all we who patients. that including The have line of not inflammatory the Evelo’s that which million worldwide, mechanism driving KOL small psoriasis XX from of biologics the this use moderate of a the are primary we oral September psoriasis We and EDPXXXX pathways the supports demonstrated in at have population, Dr. understanding The both can't in represents importance heard treated placebo. XX% multiple inflammation unmet as to segment observed happen. in the patients is two a X with good of have of resolution over And can medicine emphasize now data. safety the reported Phase humans. data answer of that last sets well data our clinical from Phase further The Since central SINTAX the clinical is with down-regulation and class Phase X of effect almost new we trial. question, comparable the yes. SINTAX coordinated lab as be The and therapeutic medicine? Daniel in targeting completely We for address And type XX:XX event, the this a can as trial both potential top have immunological basis September, reported tolerability

taking responses skin dataset inflammation validated biopsies what all dataset of consistent EDPXXXX IL-XX, cytokines or receiving deepening the animal the cellular know what The patients XX-week the from we EDPXXXX. B for follow-up clinical Part for The patients skin flash is psoriasis of now and These XX:XX of blood psoriasis was similar Many the have with persistent IL-XX first evidence X about studies. pathology after rebound with reduced This clinical was in patients EDPXXXX. seen models. of to trial of data no IL-XX, and the we cytokines multiple was they of Phase were mechanistic production resolution, cells from preclinical mechanism inflammatory immune in statistically had significant. reductions in from second of observed psoriasis. in stop action Similar human reductions long

of trial from I'm this Mark late-breaking AM that Eastern We presentation talk underpin meeting XX:XX for In of coveted clinical at the to Association evidence are Saturday external has of significant XXXX Time harness safe the to inflammatory of Broad been we going at of set the Dermatology, moment, to scientific data the delighted are for over XX:XX American chronic area create successes. discoveries new a data effective to medicines these fundamental oral, which all Phase SINTAX about can this to oral selected biology, a medicines. for hand affordable treat diseases. X recognition to announce potential Bodmer

Before doing exciting trial further that the examining data capsule. positive wanted a to clinical from announce faster today release we

both about will confidence this are a even focus expect to in our potential know, and faster Putting terms science of to capsules of all plans, is of release the Mark of clinical that been time. went The our and proportion next preclinical demonstrated this have view gives deliver able increased we with you. XX:XX than efficacy improved our Jonathan programs SINTAX we to-date, later see likely development. investigating stage Mark context XX:XX capsule medicines. drug small consistent the faster up of next. study advance will results over small the consistently profile. to Imaging together, wrap as aim development of see the potential higher now the in-depth release but clearly responders the the XX% higher in characteristics talk improve of greater response. of in to capsule of we and seen release the intestine. release we us faster that The intestine into are and have evidence, will with we results you release from up to As on the what the phase this Mark, in of release, explain these we'll and EDPXXXX to the for efficacy then protects faster up

long XX% to of radioactive the Technetium-XXm. it a upper their a emissions contents XX:XX first with on We trial, that enzymes the XX:XX camera of takes the the capsule. as showing Thanks, gets new where in capsule in does external the preclinical right right have small giving which data by an gamma this the place. of measured in release with portion get the faster a in a question takes and faster start identified volunteers jejunum, study And this that capsules Two can Simba releasing said Starting known XX:XX solution. the be place, it EDPXXXX, an used EDPXXXX the questions headline work, a The the in tested it higher got any original it tracer is is basic Scintigraphy goal how in XX% subjects stomach in The [indiscernible] of versus intestine. small protect by Technetium or how Simba human and the Simba. it evidence. for it drug from It to as the immunology asset jejunum of an volunteers there? with followed to capsule, the capsule was as X opened small in EDPXXXX EDPXXXX based XX% adjusted be soon release drug up capsule simple psoriasis a capsule can the The contains intestine the does place? in at is result, possible released intestine. when Scintigraphy of Phase human release mentioned the

The other generate at released profile efficacy. XX% lower sufficient in Phase of the [Ilium] to subjects end. the the still was This X (ph)

fast Faster release. in we faster preclinical tested exposure with higher much down as can intestine. in mice release Now the intestine this so of human overall efficacy the formulated How can version Because orally. the volunteers We'll Ilium, impact for evaluated is a human new unchanged in profile very of consistent and within but which jejunum current we profile We be let we've can significant capsule simple, the intestine drug development the significantly to versus result. of minimal release release touched before, original preclinical to a XX, induce replicate much profiles opportunity they two and down the plans effect. know has if more faster cells. comparing regulatory efficacy efficacy equivalent and well, the be less phenotype of that as for I've different stopped on a in capsules, tablets Turning a the to both on timelines. mice led is XX-fold. the profile you foundation the the the basic human up is It's posed opens, plans This in of capsules efficacy. settled. the seen once small are drug the the observations lower release lower had for This higher the the small in now beginning. efficacy clinic. the release released What to scientific in clinical XX:XX jejunum XX% only duration higher on know small about that more that the after XX question basis exert with circulating drug the to EDPXXXX inflammation provides to showed the release release up with increase higher we profile at cause of its up clear the from higher range excellent faster EDPXXXX clinical details profile with resolving path experiments given in XX:XX mice is active the is immune profile drug version efficacy this our the The EDPXXXX by tested building small work? scintigraphy substance on Based the XX% effects? does the it these the of second this using treat in worked to one. in already a the

treated drug from T-cells inhibitors Phase no the the oral We years, Part from agent, a discovery is We affected of drug the This the received transport because was in Immunology is reprogramming major animals and also in formally tolerability. conferred CDX biologics. the this mice of excellent treatment drug achieved due recipients. resolution with animals trial, effect cells follow-up the the drug a goal drug was only including of period inflammation clinical T-cells persisted to been XX:XX remained seen going elusive CDX T-cells transfer safety drugs regulatory it explain drug resulting we've from in CDX This tested X XX even for to alone, free and of stopped, now animals that during has that an portion systemic mice. with free demonstrated the deepened after anti-inflammatory did the have drug an B recipient efficacy have probably now XX:XX shown by Reduction clinical positive cells circulating this a JAK to responses the of is T-cells. number and observations which psoriasis is for not. after This treated the

benefit including intestinal medicines into in chronic property comment based safe and these molecular small that it. are diseases the The a This targeting about not not Jonathan on size it programs, update side to and allow later precisely higher of their said that our potential drug diverse The I'll anyway dexamethasone, microbes. The intestinal of due products to towards is data regulatory we've down may brief products. that this the XX:XX the just appears to pharmacological interfusion for potential which have they on physical be preclinical seen more far implications EDPXXXX, breaking the of than I'll of diseases. common subsets small breadth a their over to does other and generated mechanisms, packing for seems we've those of that only to diverse efficacy to SINTAX this year. EVs on enter axis provided important of more and limiting biologic has effective approach oral is with track characteristic So before evidence the the because axis. It finish our agent medicines. with direction EV of enable on other patients. go for unique much make then underlying T-cells restricted mechanism to that suitable use, of EVs And biology with properties extracellular clinical the Most common efforts vesicles is of densities, based with smaller levels us first to all to hand of mechanisms gut XX:XX clinic effects.

of I X moderate for readouts, our month, our to provide as trials, on and We last treatment mild, EDPXXXX XX:XX Mark. atopic the dosing several trials. announced as severe upcoming morning, planned Thank dermatitis of the like of would ongoing well began. Phase This in trial you, updates clinical

will and as into multicenter, of cohorts. reported matching results in to X up label Xb placebo execute XXXX will endpoints, cohort XX% or three a trial, with and and half topline the All a twice easy placebo-controlled secondary first moderate of quarter. being once or trial as continue trial reduction administered have dermatitis complete oriented Phase a The administered trial NRS. Australia, is XX-week X.X plan capsules of patients DLQI, for Area BSA. double-blind the in patients As an Key will We X the the dose percentage investigator EDPXXXX XX:XX patient total or of pruritus at atopic EDPXXXX are label they in the XXXX. this to capsule or as day, two total XX, a Index cells reminder, Index, XX:XX capsules the are Cohorts dosing. randomized week in one from to global of physician a according is Cohort secondary of EDPXXXX reported of POEM XX-weeks. rating endpoint of anticipated dose in XX-weeks or which times approximately explore XX. America, the once an patients scale, of cells once XXX primary expected the respectively. the a measure Key endpoints our conducted the second X.X Europe to are matching X Eczema extension daily. Dermatology of be Life the Severity assessment, this eczema one North opportunity and IGA All Quality include XXXX patients area in is patients open body numerical in placebo and times patient one Phase EDPXXXX join trial the either are daily from XX:XX and will two open Results receive extension achieving surface a of

by been EDPXXXX and As a has genus different irradiation. a is to rendered non-live from gamma reminder EDPXXXX

and healthy the results portion development the volunteer second inflammatory be development extracellular psoriasis. a remain diseases of dermatologists trials. us our their around solicit closing into EDPXXXX the will psoriasis, of feedback. third I'll it several next patients in plans to authorities advancing Simba track cohort turn community candidate clinic the This the or We in The plans. first discussions psoriasis with on meeting months next in Phase terms back and over to in now of to remarks. anticipate into excited are quarter. with registrational we vesicle of In in academic-based with will EDPXXXX We for our We bring allow for anticipate X reporting XX:XX followed in psoriasis different XX:XX by the clinical half XXXX. for regarding steps our to EV EDPXXXX have finalize hand health had

Thank XX:XX Jonathan. you,

type Mark that our all made medicine pharmaceutical support You've with a of year. that heard bold up have the and SINTAX and the of can delivered up clinical well-tolerated the to and from we The products and Jonathan the opens last new orally and of biotech that and open scientific existing effective goes inflammation about safe last quarter proved beyond convenient, statement we've we massive field stages and data medicines. progress harness treatment over

science We gut inflammatory the major system body. results. and our fundamental very have quarter, [indiscernible] with is all we've the up To underlies in of scientific uncovered that immune that and last throughout sum breakthrough. the This milestones connections, the XX:XX hit positive medical a the to clinical three the

clinical maintenance and Part Phase of patients of the responses Firstly, B psoriasis in follow-up. deepening the X

of and Evelo very XX:XX the team around where vision people disease health and to remarkable, times to closer with Secondly, EDPXXXX even globe. of stronger improve production by the thank today puts cells produced the our EDPXXXX the needed. profile of to and and circulating inflammatory and capsules. and of are position our cytokines inflammatory the move challenging systemically release improved millions disease. realizing of we resilience thirdly, cytokine And the medicines the hundreds inflammatory closer faster reduction site these for partners, living is at want SINTAX as I future commitment then of into immune This in an

strong questions. for committed open with team. have that And now We have I’ll Thank to such an XX:XX fortunate you. and exceptionally

XX:XX question the our [Operator from Instructions] line Howerton of Jefferies. And coming Chris first with

now Your line is open.

bold questions from good morning. you XX:XX much and the the taking Simba and Thanks so statement the appreciate Hi, for team.

So I do based would be respect questions would the for moderate thinking acceptable the development endpoint you're And agent approval respect question XX:XX opportunities. be going in from for programs progressing your guess an second So that -- be into what have the psoriasis? far question. to would is then with physicians. is studies, seeing What feedback business that registrational in I to mild one you psoriasis upon for my with is you. Thank XXXX that think so as you're to the strategic to

XX:XX the for Chris, year plan [indiscernible] the obviously, everybody I the of FDA. that middle interactions to with on around and authorities the Chris endpoints, thanks this regulatory do need So already question. first just and shortly. remind information question we meet meeting regulators, regards engage mentioned with is to background the relevant to you was European with complete the all

those meetings we through endpoint. be we moment, skin XX, So obviously is to likely the so a endpoint what or to anticipate to would finalize clear clear would nearly need be. get clinical the that At score the PGA

know With XX:XX corporate of of clear forward have We've even that of will that remain do. opportunity be first there and medicines the we been the unashamed a the and to what so partnerships, medicines Chris. in pipe with be to is forming strong the always of regards registration patients that studies one monoclonal with with a that capture become philosophically that we the enormous the could said innovation question. we've part create context key biotech and than very that, which and something is you those is We same to becomes of have medicine science, and our biotech. to moving Evelo completely towards more have time, openness of rare always transformative So biotech cannot that’s massive forever we and best is to At that and of to, you an it in to as breadth do I Chris always integrate the SINTAX potential independent opportunity partners and what on history own. way healthcare answer the of will opportunities the partnering antibodies company. to to that been develop corporate SINTAX key do a company transform allow us that translates partnering But together

value, allowing and build remaining capturing lot of fully products company. forward of So and a forward XXXX us that the towards including integrated the to integrate

Awesome. then right. Thank forward. much and everything all so appreciate Okay, XX:XX moving you

Chris. Thanks, XX:XX

XX:XX Our coming of the Markets. question next Gary from BMO Nachman Capital from line

Your line is now open.

this XXXX, formulations? clinical from possible you'll a the psoriasis there for who earlier good earlier into small was intestine? drug before XX:XX additional Phase to And a bridging of didn’t a outcome. two releasing on for Hi, good GI I get in with morning. the there then the XXX% And just release study study follow-ups. these side to release But XX% that a are Data ever and couple a clearly earlier effects X any patients is it is have of moving small into chance [indiscernible] quick need

question, XX:XX Gary, me the So, Gary. first doing? sorry. on are write enough. quickly Hey, Just couldn't you I How remind

XX:XX Simba. it actually, I've got

if GI GI any are The effect? XX:XX side there

regarding Yes, XX:XX drug.

full like be ecstatic, models. and led are the remind preclinical over at to cetera. concerned so et very absolutely, about no, antibody their, safety all to core faster of around said clean XXX continue over one Gary, including and regards could animal you, on profile we've the -- models is extremely small that great stage. better at nothing XX% that terms better my just question the first the and early XX:XX in importantly, this the as the subjects safe of assets, of and in of in XX% principles Gary, we've Gary, life a to also core and well with seeing to to studies to we human an consistently been of clinical and and a versus includes And always result, tolerated very, very capsule. efficacy science XXX%, exposure release Having a and we intestine that piece see platform with regards consistently you life the release do to In be possible tolerability, it’s done, it’s in know, the So

is So this in And releasing the in remarkable type of would we that like encouraging is very jejunum quickly XX:XX and very, result where clinic. the for we're what seeing XX% see links do we a of requirement any question, next do Obviously, conversations to to don't your then that. to have have bridging be studies, terms in there'll we with regulators. anticipate the

We a as without moving details possible atopic that, of follow as more study able will we'll that any into be Phase quickly and expect be studies. to but do to we dermatitis X on clinical order existing impacting in our short

pick that's And additional the And X already? will it great. to on interim and us at what atopic derm, end? bit in present just Phase XXXX one Thanks. so and will be, both data XXXX? more and the Xb congrats And that a late-breaker just Okay, XX:XX from between be what there XXXX AAD, you in for should then, then we've or what differences seen any or the remind the atopic you getting see XXXX derm ultimately expecting we’d the little could data you'll pursue

I'll in Yes, XX:XX XXXX done let XXXX we’ll back you let that I first careful have question. know, I between terms again, Mark moment. difference question a should in [indiscernible] the and the me at it of third the so XXXX, take be second to come take

similar across two and actually. line of a inflammation, historically. is as report both if in areas how we'll of soon XXXX what data one is To will Phase degree of inflammation, we're topline for there's atopic including We which could focus they dermatitis, have get dermatitis, it's out could data, the indications potentially the looking XXXX there, to efficacy from an we example, result and terms different a in atopic see endpoints which segment So seen forward many necessarily a inflammation it. look clear the develop cetera. which et move we XXXX for XXXX positive proof at is could us of clinical with what a breadth way It's at ability patient essentially to not we and way different principle and XXXX. to so a what Xb expectation indication very that to beauties potentially we've get be of directions, with efficacy address XX:XX to the positive clear XXXX different the dermatitis top were in of biopsies we clinic have obviously And be preclinically should in is, interim, is segments result neuro also will and could atopic what in false for done the of many there develop to we've XXXX some we will and in example different not positive on -- products many we fairly the in

how do So we want that XX:XX Mark, could lots forward. of terms take the to XXXX of different ways it you answer question on versus different? in XXXX

points the Thanks, microbes that our intestinal you it’s a resident that EDPXXXX seven small is the and was EDPXXXX are colonization our was Toll-like action, mechanism slightly receptors or process a and and resident most potent dead is microbes one closely probably sample that through just about find products. this samples, is when There a from which isolated reinforce irradiation taking [indiscernible] [indiscernible] at properties. actually -- patient vesicles a things Maybe the different fact three come these is in at a isolates, very four remission, extracellular by distinct quite but through from that direct activity. live pattern EDPXXXX, molecular a of stool effectively of range including point and being manufacturing sure. Gary. types we're would from action Yes, thing microbes when activity. biochemistry This the receptors, it. XX:XX we it's good sample biotherapeutic overlapping, what XX:XX bacterial gamma not from of EDPXXXX. different not And one we products in point different which we potential pharmacological recognition from that that other out be in for as in little was impact patterns of the outset part design has the work to of which strategy takes it's a find The taxonomically talked with of a other lot when those of of a to -- taxonomy, patient range look have is

of due this all gut. microbial with host we're looking what clinically preparation seen interactions direct activity and in cells with preclinically the So to the for is we've that

XX:XX the remember question your other so Gary to presentation, I regards So, – with AAD

XX:XX anyone. If

obviously that we've XX:XX of so are thrilled, selective we Yes, yes, first been all late-breaker.

mid-stage community validation unusual The that derm As by potential is clinical to doing. for trial. we're happen know it's for company, what seeing great for think very you the biotech I

provide will We today do been data said, obviously folks out color, as three line on efficacy the than able That obviously reported as obviously beyond well top recently. of we've to far. the pieces key so we've more

would to but So, encourage to listen it. you I

XX:XX Great.

you. thank Okay,

to I’ll XX:XX Gary. later, XX:XX time All Saturday morning Thanks, AM right. that you Gary. good listen. put on

next coming the Our question line Joseph of from Cowen. Thome XX:XX with

line Your open. is

morning is going expect, the the updated similarly that the and in about you kinetics Or the one might formulation candidate the EV XX:XX differentiated maybe, same of, taking higher Hi, as is all? generation be release should using than this there candidate, you first the candidates better thank for with formulation, Maybe the are aware EV and at do there. different anything intestine in questions. that you or release efficacy genetics? And on be Good release our to the first jejunum. kind

to with skiing today, hi, you later Yes, Look Joe. forward hopefully. XX:XX so

capsule as but is that, faster of release platform to the opposed it's product related. formulation beauty related So, the

should or going microbes dramatically applicable So [indiscernible] whether we're for forward. it's about EVs, profile, improved be talking release a it all

And anticipate result result. have we microbes we're said to everything it EVs. the with straight doing efficacy really So possible thrilled as we in the again we to as across see best we -- I going already, well. are we away And it very drive use It's for increase but EV it significant expected. or having potential will we're could that

I do other segments? before XX:XX Or they on combination patients have severe in Perfect. need I how then data is call, you combination week, physicians uptick that for showing XXXX that psoriasis clinically, and approach. have the patients potentially benefit And more are KOL mentioned this? in know therapies? able using And in to the a severe straightforward is to you get reimbursement guess more potentially additional prescribe combinatorial

real event had KOL world XX:XX in actually recently. the very was straightforward, at Yes, briefly on very it so we the touched

predicted for world XXXX. then patients with XXXX use flares start example, very equivalent will a expect expect on acute moving through maintenance example, combination and for with very then least this for gold and very at to topicals go through of Joe, go Q at we've the will, to very, will straightforward mild off example doing standard, on initially are So are, be be been so be in then where potentially topical, step practice very, use treat in of it, the through what what moderate moderate it in used know, straightforward real mild will that clinicians we to -- and of least we should you have topical in and may, that, to That's certain but straightforward. initially essentially we'll segments monotherapy and we

So very we think straightforward. very, to going it's be

and later very today. see thank Perfect, you XX:XX you much

to Thanks, Look forward that. XX:XX Joe.

next Our from Cantor. coming question the line XX:XX with Kluska Kristen of

open. Your is line

Hey, XX:XX good everybody. much so for questions. the taking morning Thanks

wanted targeting the reported it topical the ask today, data I -- cells? And small new of that the intestinal cells immune macrophages? intestine correlates and specific you relates the targeting to the also with how With how resident of and to the dendritic

XX:XX that. your Good morning, voice. let always Mark hear I'll Kristen, good answer to

of detailed question the higher more actually, more the to, includes at into throughout parts cells the publications with support interesting -- longitudinally about upper the and are in XX:XX nice we've of jejunum. the jejunum, for of which Yes, short immune throughout preclinical in particular dendritic we distribution Kristen at release this in very gut higher -- which densities got really hypothesis a cells the of interestingly looking the that's and referred gut relatively this is the the view the

target. immune things. other XX:XX the the that you to actually if stop the The thing So system, is, place to but we primary be have immune the outset, -- hypothesis role job it’s disaster, those of gut think into system about the constantly it stomach stuff a and of amounts gut would a responses from things, body all be we and immune responding to coming the if while massive as the are well, mouth against had foreign because the the

stimulus immunology, Simba the the actually we a back of this the dose taking people So and it's and actually we're stuff you of what very even from right will actually the are that's at a against infection but intestine. to small and gets most medicines ability a face emphasizes it, of of of natural Immune we've need though and providing at that's protect intestinal true, built to was it the think that's step multiple natural foreign uproar. system we in it’s foreign continued food will what about of the to the because like what against things if the it’s that's inflammatory always everything levels engage on as immune the we're small, continuously in but inflammation. harnessing it in an we prevented types are XX:XX was, appears -- a potent parts with about systems much, of with So sort harnessing be the pathways higher complicated level, understanding and talk the to in -- gut think ingest barrels else doing taken prevent -- function to on those maintain early resolution is actually at always And homeostasis responses of the of systems thinking is drugs focused coming food into cancer of I level, immunology you've one that systems got types microbes an small more but principal it doing and for that one some doing, being essentially doing we that, that's pharmacological these all of environmental is

all the not way final the body foreign by do to the were responses, So point without homeostasis the intervention, pathway does. systems that, suppressive most able targeted to antigens what normally ourselves the training because down suppress me XX:XX to. occurs immune not taken normal system is reestablish to single the do just works the immune is if reaction of exposed you naturally have adverse generally of as are parallel the this one it's gut is in we molecular And Kris, give

that terms immune in this clear Hope immune we're that in So enough. clinical it's the whole describing the complete profile the cells of gut. gut distribution predominant the for was requirement sense system. in of functionally terms of And

that you Thank wanted that. the cetera. was. light you've administration in for pediatric? market for route communicated, safety you. that it you oral then about Yes psoriasis, view XX:XX an or the perhaps for et ask stat opportunity have about therapy about everything to there anything is the And emphasize you of pediatric and Is you this say how for different of KOLs Thank would the

XX:XX terms Yes, just so should responding I to psoriasis go the in questions. above of

you've And them limitation more look parent, if prescribe XX:XX a children than in and a very inflammatory you inflammatory very, don't populations. well I side put to you massive particularly of it pediatric a anybody obviously it in and atopic population. an of the disease it’s has it four a inflammatory to and the context, that, is but safety as if becomes to obviously about those hard children HP's even normally. So even pediatric just all who very got issue to want at And full of when trials current stay, tolerability tolerated of one trial with dealing products, paramount I diseases in children interest product. And was know we're condition. things almost major is and

which the in tolerability more essentially pediatric in I'll massive medicines population, obviously how are which is a teenagers so it swallow inflammatory relatively suffer and teenagers Obviously, ones do particular, who capsules. unique ideally profile, have perspective. emphasizing talking about what piece able the you is use even give safety you're inflammation broadly. HP's is of the XX:XX a So The we keep from completely and formulation children, diseases, if is but on straightforward a tablets next and and on unruly in little particularly world touching suited to from to we're

obviously to cannot of in capsule administration example very done issue is So delivery for terms formulation go patients. younger an in that no through issue be young oral

for clear the pediatric thing are the have formulations, in working I and allow and very, instance we all potential think the that's for population happy path to progress be that that, get injection in for able most around excited here about issues potential we're important would a Kristen. population, the So pediatrics. forward of see first doing very is that. huge we'll on pediatric no already we Confident to we're what which in really work basis, And alternative so

XX:XX you. Great, thank

Vikram question XX:XX And the our from Stanley. next line Purohit coming from of Morgan

Your line is open.

Gospel is morning, Good XX:XX for everyone. Vikram. This on

plan one in have question, regulatory mind study EDPXXXX any And the the size? guide release like and input We and you terms has study first to design on in of have is, here? question design the been there that what the would of look clinical capsule,

single right the the focus right, on appreciate I topic. question, morning. good Gospel, XX:XX one focused think the and I you're

release significant going patients. it importantly, in Great of able responses that are we likelihood improves and capsule very to So we're a proportion with the be dramatically to faster again, most thrilled the get.

the got data just have We Gospel.

course, expect we a as regulators, going and there working of expecting not sense we're what but interacted dermatitis that, we not around on to expect will we're informal from and with Gosp. directional more with is will somewhere show designs quickly to atopic So I Phase we expect in interact year clinical results of that first likely have follow yet in formal will that. study X get yet half through have regulators guidance, powered we'll would study due and Certainly, clear but next with move we forward very benefit

XX:XX All much. right. Thank you very

XX:XX Absolutely.

Gill to closing Simba I like XX:XX turn now any And questions the this would I'm further over at for back to showing call time. remarks. no

you very Thank XX:XX much.

now throughout and So always exciting continue to us, conference mice things that the a very where fundamental exists, the is platform XX:XX realize biotech and where of and and for those but to human thanks said, small we linked from times body. uncovered to so progress from this very of extremely this plays and remarkably conversations that regulating medicine of that to investor very in have discussions we've excited is we and very science Evelo, we of strength-to-strength, didn't stage a confident the role systemic know what very some rare completely intestinal before right be inflammation have that going axis biology able in glasses we're new at what's fundamental at ski exists on one much is had wine. vision clear we slopes interesting we've But community and a the obviously, era existed broad that situations clear for about are the are everyone, it

level. something a forward next very that fantastic very release keeping look takes data can updated. X We've generated probably a today As got make And from lot to So Mark, place from in response. don't have to to showing everybody harness much, clinical and very we connection of we flow in said microbes needed now of you've and we're in Mark continuous and between and inflammatory key safe including the us news inflammation it that very faster heard today's clear gut really to evolutionary future. that repeatedly the that's near everyone. uncovered XX:XX links was capsule formulation sure, tolerated we've the the they trigger quickly, systemic the as immunity well a positive Phase Thanks background systemic

you XX:XX conclude your our Thank gentlemen, for that does conference today. and Ladies for participation.

You may disconnect. now